Hormone replacement therapy and cancer risk: A systematic analysis from a network of case-control studies

2003 ◽  
Vol 105 (3) ◽  
pp. 408-412 ◽  
Author(s):  
Esteve Fernandez ◽  
Silvano Gallus ◽  
Cristina Bosetti ◽  
Silvia Franceschi ◽  
Eva Negri ◽  
...  
Keyword(s):  
Hormone Replacement Therapy ◽  
Cancer Risk ◽  
Replacement Therapy ◽  
Hormone Replacement ◽  
Case Control ◽  
Case Control Studies ◽  
Systematic Analysis

scholarly journals Use of hormone replacement therapy and risk of venous thromboembolism: nested case-control studies using the QResearch and CPRD databases

BMJ ◽  
2019 ◽  
pp. k4810 ◽  
Author(s):  
Yana Vinogradova ◽  
Carol Coupland ◽  
Julia Hippisley-Cox
Keyword(s):  
Hormone Replacement Therapy ◽  
Venous Thromboembolism ◽  
Replacement Therapy ◽  
Odds Ratio ◽  
Index Date ◽  
Adjusted Odds Ratio ◽  
Hormone Replacement ◽  
Case Control ◽  
Case Control Studies ◽  
Nested Case Control

AbstractObjectiveTo assess the association between risk of venous thromboembolism and use of different types of hormone replacement therapy.DesignTwo nested case-control studies.SettingUK general practices contributing to the QResearch or Clinical Practice Research Datalink (CPRD) databases, and linked to hospital, mortality, and social deprivation data.Participants80 396 women aged 40-79 with a primary diagnosis of venous thromboembolism between 1998 and 2017, matched by age, general practice, and index date to 391 494 female controls.Main outcome measuresVenous thromboembolism recorded on general practice, mortality, or hospital records. Odds ratios were adjusted for demographics, smoking status, alcohol consumption, comorbidities, recent medical events, and other prescribed drugs.ResultsOverall, 5795 (7.2%) women who had venous thromboembolism and 21 670 (5.5%) controls had been exposed to hormone replacement therapy within 90 days before the index date. Of these two groups, 4915 (85%)and 16 938 (78%) women used oral therapy, respectively, which was associated with a significantly increased risk of venous thromboembolism compared with no exposure (adjusted odds ratio 1.58, 95% confidence interval 1.52 to 1.64), for both oestrogen only preparations (1.40, 1.32 to 1.48) and combined preparations (1.73, 1.65 to 1.81). Estradiolhad a lower risk than conjugated equine oestrogen for oestrogen only preparations (0.85, 0.76 to 0.95) and combined preparations (0.83, 0.76 to 0.91). Compared with no exposure, conjugated equine oestrogen with medroxyprogesterone acetate had the highest risk (2.10, 1.92 to 2.31), and estradiol with dydrogesterone had the lowest risk (1.18, 0.98 to 1.42). Transdermal preparations were not associated with risk of venous thromboembolism, which was consistent for different regimens (overall adjusted odds ratio 0.93, 95% confidence interval 0.87 to 1.01).ConclusionsIn the present study, transdermal treatment was the safest type of hormone replacement therapy when risk of venous thromboembolism was assessed. Transdermal treatment appears to be underused, with the overwhelming preference still for oral preparations.

scholarly journals Risk of hand osteoarthritis in new users of hormone replacement therapy: A nested case-control analysis

Maturitas ◽  
2020 ◽  
Vol 132 ◽  
pp. 17-23
Author(s):  
Theresa Burkard ◽  
Marlene Rauch ◽  
Julia Spoendlin ◽  
Daniel Prieto-Alhambra ◽  
Susan S. Jick ◽  
...  
Keyword(s):  
Hormone Replacement Therapy ◽  
Replacement Therapy ◽  
Hormone Replacement ◽  
Case Control ◽  
Hand Osteoarthritis ◽  
Control Analysis ◽  
Case Control Analysis ◽  
Nested Case Control
Sign in / Sign up

Export Citation Format

Share Document